Literature DB >> 27479645

Proposing prognostic thresholds for lymph node yield in clinically lymph node-negative and lymph node-positive cancers of the oral cavity.

Phoebe Kuo1, Saral Mehra1,2, Julie A Sosa3,4,5, Sanziana A Roman3, Zain A Husain2,6, Barbara A Burtness2,7, Janet P Tate8, Wendell G Yarbrough1,2,9, Benjamin L Judson1,2.   

Abstract

BACKGROUND: Prognostic lymph node yield thresholds have been identified and incorporated into treatment guidelines for multiple cancer sites, but not for oral cancer. The objective of this study was to identify optimal thresholds in elective and therapeutic neck dissection for oral cavity cancers.
METHODS: Patients with oral cavity cancers in the National Cancer Database (NCDB) were stratified into clinically lymph node-negative (cN0) and clinically lymph node-positive (cN+) cohorts to reflect the differing surgical management for these diseases. Univariate and multivariate analyses were performed to assess the relation between lymph node yield and overall survival, adjusting for other prognostic factors. Thresholds derived from the NCDB were validated in the Surveillance, Epidemiology, and End Results database.
RESULTS: In patients with cN0 cancers of the oral cavity from the NCDB, those who had <16 lymph nodes had significantly decreased survival. The proportion of positive lymph nodes was higher for patients who had ≥16 lymph nodes (27.2% vs 16.3% for < 16 lymph nodes; P < .001). This threshold was validated in 2715 lymph node-negative cancers from SEER, with a mortality hazard ratio of 0.825 for ≥ 16 lymph nodes (95% confidence interval, 0.764-0.950; P = .004). In patients with cN + oral cavity cancers from the NCDB, groups with <26 lymph nodes had significantly decreased survival. This threshold was validated in 1903 lymph node-positive cancers from SEER, with a mortality hazard ratio of 0.791 (95% confidence interval, 0.692-0.903; P = .001). Academic centers, higher volume centers, and geographic location predicted higher lymph node yields.
CONCLUSIONS: More extensive neck dissection (≥16 lymph nodes in cN0, ≥ 26 lymph nodes in cN+) was associated with better survival. Further evaluation of practice patterns in lymph node yield may represent an opportunity for improved quality of care. Cancer 2016;122:3624-31.
© 2016 American Cancer Society. © 2016 American Cancer Society.

Entities:  

Keywords:  head and neck cancer; lymph node; neck dissection; oral cavity; quality; survival

Mesh:

Year:  2016        PMID: 27479645     DOI: 10.1002/cncr.30227

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Association of Number of Dissected Lymph Nodes With Survival in Clinically Node-Negative Oral Cavity Squamous Cell Carcinoma Patients Undergoing Primary Surgery: A Population-Based Analysis.

Authors:  Chiaojung Jillian Tsai; Junting Zheng; Zhigang Zhang; Nadeem Riaz; Shrujal S Baxi; Richard J Wong; Nancy Y Lee
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-10-01       Impact factor: 6.223

2.  Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline.

Authors:  Shlomo A Koyfman; Nofisat Ismaila; Doug Crook; Anil D'Cruz; Cristina P Rodriguez; David J Sher; Damian Silbermins; Erich M Sturgis; Terance T Tsue; Jared Weiss; Sue S Yom; F Christopher Holsinger
Journal:  J Clin Oncol       Date:  2019-02-27       Impact factor: 44.544

3.  Metastatic lymph node burden predictive of survival in patients undergoing primary surgery for laryngeal and hypopharyngeal cancer.

Authors:  Yeonjoo Choi; Manal Bin-Manie; Jong-Lyel Roh; Kyung-Ja Cho; Yoon Se Lee; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  J Cancer Res Clin Oncol       Date:  2019-07-27       Impact factor: 4.553

4.  Prognostic value of lymph node involvement in oral squamous cell carcinoma.

Authors:  Jan Oliver Voss; Lea Freund; Felix Neumann; Friedrich Mrosk; Kerstin Rubarth; Kilian Kreutzer; Christian Doll; Max Heiland; Steffen Koerdt
Journal:  Clin Oral Investig       Date:  2022-07-27       Impact factor: 3.606

5.  Lymph node yield as a prognostic factor in clinically node negative oral cavity squamous cell carcinoma.

Authors:  Ahmad A AlTuwaijri; Mohammed A Alessa; Alanoud A Abuhaimed; Reenad H Bedaiwi; Mohammad A Almayouf; Majed M Albarrak; Saleh F Aldhahri; Khalid H Al-Qahtani
Journal:  Saudi Med J       Date:  2021-12       Impact factor: 1.422

6.  Prognostic significance of lymph node yield and lymph node ratio in patients affected by squamous cell carcinoma of the oral cavity and oropharynx: Study protocol for a prospective, multicenter, observational study.

Authors:  Oreste Iocca; Alessio Farcomeni; Armando De Virgilio; Pasquale Di Maio; Paweł Golusinski; Luca Malvezzi; Raul Pellini; Wojciech Golusinski; Christopher H Rassekh; Giuseppe Spriano
Journal:  Contemp Clin Trials Commun       Date:  2019-01-14

7.  Prognostic value of the nodal yield in head and neck squamous cell carcinoma: A systematic review.

Authors:  Willem W B de Kort; Sybren L N Maas; Robert J J Van Es; Stefan M Willems
Journal:  Head Neck       Date:  2019-04-10       Impact factor: 3.147

8.  Association of a multiple-step action with cervical lymph node yield of oral cancer patients in an Asian country.

Authors:  Ching-Chieh Yang; Bor-Hwang Kang; Wen-Shan Liu; Chun-Hao Yin; Ching-Chih Lee
Journal:  BMC Oral Health       Date:  2021-01-13       Impact factor: 2.757

9.  Metastatic Lymph Node Burden and Survival in Oral Cavity Cancer.

Authors:  Allen S Ho; Sungjin Kim; Mourad Tighiouart; Cynthia Gudino; Alain Mita; Kevin S Scher; Anna Laury; Ravi Prasad; Stephen L Shiao; Jennifer E Van Eyk; Zachary S Zumsteg
Journal:  J Clin Oncol       Date:  2017-09-07       Impact factor: 50.717

10.  Recommendation for incorporation of a different lymph node scoring system in future AJCC N category for oral cancer.

Authors:  Ching-Chih Lee; Yu-Chieh Su; Shih-Kai Hung; Po-Chun Chen; Chung-I Huang; Wei-Lun Huang; Yu-Wei Lin; Ching-Chieh Yang
Journal:  Sci Rep       Date:  2017-10-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.